# Short and long term central peripherally inserted catheters in hematological malignancy patients: clinical outcomes and safety. Single centre experience

**Authors:** Carlos Gómez Calcetero, Juanita Granados Diaz, Adriana Aya Porto, Andres Forero Romero, Maria López Mora, Paola Omaña Orduz, Jorge Daza Buitrago, Maira Murcia Linares, Viriginia Abello Polo

PMC · DOI: 10.3332/ecancer.2025.2044 · ecancermedicalscience · 2025-11-20

## TL;DR

This study examines the safety and complications of PICC and MC catheters in patients with blood cancers, finding low complication rates with proper care.

## Contribution

The study provides real-world complication rates and care strategies for PICC and MC use in hematological malignancy patients.

## Key findings

- Catheter-associated thrombosis and bloodstream infection rates were 3.2% and 3.7%, respectively.
- Complication rates per 1,000 catheter days were 0.31 for thrombosis and 0.83 for infection.
- Multidisciplinary care and protocols reduced variability and complications.

## Abstract

To characterise the population and describe the complications in patients with hematologic malignancies who underwent implantation of a peripherally inserted central catheter (PICC) or midline catheter (MC) for the administration of chemotherapy or oncologic support.

The retrospective descriptive study included patients with hematologic malignancies who underwent PICC or MC implantation between July 2022 and 2024. All patients are part of the institution-based prospective observational Evidence – Verification – Analysis study. Variables related to device type were obtained from the vascular access and infection control group databases. Frequencies and percentages were used for categorical variables, and medians and interquartile ranges were used for numerical variables. Event rates per 1,000 days were calculated for complications.

156 patients with 249 events were included. All devices were high-flow and bi-lumen, the most common indication was chemotherapy administration, and the most common site was brachial. The median days in use for lymphoma and acute leukaemia were 67.5 and 24 days, respectively. The rates of catheter-associated thrombosis and catheter-associated bloodstream infection were 3.2% and 3.7%, respectively. The rates of catheter-related venous thrombosis per 1,000 catheter days and catheter-related bloodstream infection per 1,000 catheter days were 0.31 and 0.83, respectively.

A multidisciplinary approach, thorough initial venous assessment, a strong support network, adherence to care protocols and continuous patient education have helped to reduce variability in care and lower complication rates at our institution.

## Linked entities

- **Diseases:** lymphoma (MONDO:0003659)

## Full-text entities

- **Diseases:** CRBIs (MESH:D055499), death (MESH:D003643), hematological diseases (MESH:D006402), chronic leukaemias (MESH:D015451), complication (MESH:D008107), HL (MESH:C538324), vein thrombosis (MESH:D012170), thrombosis (MESH:D013927), CFU-LLM (MESH:D016399), phlebitis (MESH:D010689), deep vein thrombosis (MESH:D020246), myeloma (MESH:D009101), infection (MESH:D007239), acute leukaemia (MESH:D054218), Cancer (MESH:D009369), pneumothorax (MESH:D011030), bacteremia (MESH:D016470), ALL (MESH:D054198), thrombocytopenia (MESH:D013921), leukaemia (MESH:D015458), Hodgkin and non-Hodgkin lymphomas (MESH:D008228), lymphoma (MESH:D008223), bleeding (MESH:D006470), CRVT (MESH:D056824), -related bloodstream infection (MESH:D018805), Acute myeloid leukemia (MESH:D015470), oncologic (MESH:D000072716), pulmonary embolism (MESH:D011655), hematologic malignancies (MESH:D019337)
- **Chemicals:** Br - ESHAP (-), venetoclax (MESH:C579720), Dexamethasone (MESH:D003907), Rituximab (MESH:D000069283), DA (MESH:C025953), Lenalidomide (MESH:D000077269), Bortezomib (MESH:D000069286), ABVD (MESH:C034632), Daratumumab (MESH:C556306), azacitidine (MESH:D001374)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950876/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950876/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950876/full.md

---
Source: https://tomesphere.com/paper/PMC12950876